Furosemide (subcutaneous, scPharmaceuticals) vs Torsemide (Soaanz)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: NKCC2 · full Heart Failure pipeline

Furosemide (subcutaneous, scPharmaceuticals) · FUROSCIX

Marketed by scPharmaceuticals and partners

Approved in Heart FailureSmall molecule (drug-device combination)
Weak signal

NCT03458325 · Phase 3 · completed

This was a small, open-label, non-randomized single-group study: 25 participants received Furoscix and were compared with propensity-matched historical claims controls rather than a concurrent randomized control. The primary endpoint was 30-day healthcare utilization cost, an economic measure. A single-group study that is not an extension of a prior randomized trial is weak evidence under the rubric.

Reported efficacy

Healthcare Utilization Costs (Day 0 - Day 30): Healthcare Utilization Costs (Day 0 - Day 30): Furoscix Infusor Prospective Treatment — HF-related healthcare costs: 2920.3 US Dollars (Standard Deviation 7073.2); Overall healthcare costs: 7512.3 US Dollars (met)

Result source: NCT03458325

Torsemide (Soaanz)

Marketed by Sarfez Pharmaceuticals

Approved in Heart FailureSmall molecule (reformulation)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFurosemide (subcutaneous, scPharmaceuticals)Torsemide (Soaanz)
CV death or HF hospitalisation—Not posted · NCT04533997—Not reported
HF hospitalisation—Not posted · NCT04533997—Not reported
CV death—Not posted · NCT04533997—Not reported
KCCQ clinical summary, change—Not posted · NCT04533997—Not reported

CV death or HF hospitalisation

Furosemide (subcutaneous, scPharmaceuticals)
—Not posted · NCT04533997
Torsemide (Soaanz)
—Not reported

HF hospitalisation

Furosemide (subcutaneous, scPharmaceuticals)
—Not posted · NCT04533997
Torsemide (Soaanz)
—Not reported

CV death

Furosemide (subcutaneous, scPharmaceuticals)
—Not posted · NCT04533997
Torsemide (Soaanz)
—Not reported

KCCQ clinical summary, change

Furosemide (subcutaneous, scPharmaceuticals)
—Not posted · NCT04533997
Torsemide (Soaanz)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Torsemide (Soaanz): no structured comparison results are available for Heart Failure.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Furosemide (subcutaneous, scPharmaceuticals): 3 of 4 rows · Torsemide (Soaanz): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFurosemide (subcutaneous, scPharmaceuticals)
Dropout rate
4%a
NCT03458325 · Phase 3 · Heart Failure · phase 3
show 4 more results
0%<= 11 BAN-ADHF, Furoscix
NCT05528588 · Phase 2 · registry result, not featured evidence
—Subcutaneous Furosemide
NCT05528588 · Phase 2 · registry result, not featured evidence
0%≥ 12 BAN-ADHF, Furoscix
NCT05528588 · Phase 2 · registry result, not featured evidence
2.9%
NCT04593823 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT03458325 · Phase 3 · Heart Failure · phase 3
show 4 more results
—<= 11 BAN-ADHF, Furoscix
NCT05528588 · Phase 2 · registry result, not featured evidence
—Subcutaneous Furosemide
NCT05528588 · Phase 2 · registry result, not featured evidence
—≥ 12 BAN-ADHF, Furoscix
NCT05528588 · Phase 2 · registry result, not featured evidence
—
NCT04593823 · Phase 2 · registry result, not featured evidence
Serious AEs
25%a
NCT03458325 · Phase 3 · Heart Failure · phase 3
show 4 more results
—<= 11 BAN-ADHF, Furoscix
NCT05528588 · Phase 2 · registry result, not featured evidence
28.6%Subcutaneous Furosemide
NCT05528588 · Phase 2 · registry result, not featured evidence
—≥ 12 BAN-ADHF, Furoscix
NCT05528588 · Phase 2 · registry result, not featured evidence
35.3%
NCT04593823 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
infusion site bruising 29.2%
infusion site pain 29.2%
dizziness 12.5%
NCT03458325 · Phase 3 · Heart Failure · phase 3
show 2 more results
increase in creatinine > 0.3 from discharge to end-of-study visit blood test 14.3%
potassium ≤ 3.0 2.9%
NCT05528588 · Phase 2 · registry result, not featured evidence
hypokalaemia 20.6%
infusion site pain 14.7%
renal impairment 14.7%
NCT04593823 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Furosemide (subcutaneous, scPharmaceuticals)

HF Hospitalization 4.2% (n=24) @ 4.3wk
responder rate · % of participants
No placebo or comparator arm
NCT03458325 · Phase 3 · Heart Failure · phase 3 · converted to % from 1 Participants as posted
KCCQ-12 29.9 score @ 4.3wk
absolute value · score
No placebo or comparator arm
Summary Score
NCT03458325 · Phase 3 · Heart Failure · phase 3
show 1 more result
42.8 score @ 4.3wk
Summary Score
NCT03458325 · Phase 3 · Heart Failure · phase 3
Cumulative Urine Output 24 h 34 vs 22.6 Oral Furosemide mg @ 0.14wk
absolute value · mg
NCT05528588 · Phase 2 · registry result, not featured evidence
show 1 more result
29.8 vs 22.6 Oral Furosemide mg @ 0.14wk
NCT05528588 · Phase 2 · registry result, not featured evidence
Win 228 vs 206 Continued Medical Therapy count
ratio to baseline · count
NCT04593823 · Phase 2 · registry result, not featured evidence
HF Urgent Visit 0% (n=34) vs 0% (n=17) Continued Medical Therapy @ 4.29wk
event count · % of participants
NCT04593823 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
NT-Pro BNP -7.195% (n=30) vs -2.17% (n=11) Continued Medical Therapy @ 4.3wk
percent change · % of baseline
NCT04593823 · Phase 2 · registry result, not featured evidence
HF Event Free Survival 0.76 vs 0.47 Continued Medical Therapy months @ 4.3wk
time to event · months
NCT04593823 · Phase 2 · registry result, not featured evidence · converted to months from 23.2 days as posted
KCCQ-12 51.55 vs 36.68 Continued Medical Therapy score @ 1wk
absolute value · score
NCT04593823 · Phase 2 · registry result, not featured evidence
show 1 more result
55.8 vs 45.33 Continued Medical Therapy score @ 4.29wk
NCT04593823 · Phase 2 · registry result, not featured evidence
6MWD - Change 269 vs 201 Continued Medical Therapy m @ 1wk
absolute change · m
NCT04593823 · Phase 2 · registry result, not featured evidence
show 1 more result
292.3 vs 192.3 Continued Medical Therapy m @ 4.29wk
NCT04593823 · Phase 2 · registry result, not featured evidence
Serum Creatinine Change mg/dL 1.496 vs 1.696 Continued Medical Therapy mg/dL @ 0wk
absolute change · mg/dL
NCT04593823 · Phase 2 · registry result, not featured evidence
show 3 more results
1.611 vs 1.894 Continued Medical Therapy mg/dL @ 0.43wk
NCT04593823 · Phase 2 · registry result, not featured evidence
1.648 vs 1.811 Continued Medical Therapy mg/dL @ 1wk
NCT04593823 · Phase 2 · registry result, not featured evidence
1.641 vs 2.01 Continued Medical Therapy mg/dL @ 4.29wk
NCT04593823 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Furosemide (subcutaneous, scPharmaceuticals)'s landscape · Torsemide (Soaanz)'s landscape